HBV基因型与聚乙二醇干扰素疗效关系及病理变化

目的 研究乙型肝炎病毒(HBV)基因型与聚乙二醇干扰素(PEG-IFN)疗效关系及不同基因型治疗后的肝脏病理改变.方法 采用实时荧光PCR基因分型法,分析48例用聚乙二醇干扰素治疗的CHB患者基因型对抗病毒疗效的影响和病理改变情况.结果 在治疗结束时,B型与C型对比,两种基因型的ALT复常率、HBeAg阴转率、HBeAg转换率、HBV DNA转阴率及病理结果改善率无明显差异(P>0.05);在随访48周后,B基因型的持续应答率明显高于C基因型(P<0.05).结论 HBV基因型是预测聚乙二醇干扰素疗效的重要因素,B基因型的持续应答率明显高于C基因型.

Correlation of HBV genotypes to the therapeutic effect of PEG-interferon and the pathological changes of the liver of chronic hepatitis B patients

OBJECTIVE: To study the correlation of HBV genotypes to the response to PEG-interferon alpha (PEG-IFN) in chronic hepatitis B (CHB) patients. METHODS: Real-time fluorescent PCR was used for HBV genotyping in 48 CHB patients, and the therapeutic effects of PEG-IFN and hepatic pathological changes were observed. RESULTS: No obvious differences were noted in ALT and HBV DNA levels or negative rate for HBeAg between patients with genotypes B and C (P>0.05). The sustained response rate was significantly higher in genotype B than in genotype C patients 48 weeks o after the therapy. CONCLUSION: HBV genotype is the main factor for predicting PEG-IFN therapy response in CHB patients, and the sustained response rate is significantly higher in genotype B than in genotype C patients.